Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection : AIDS Clinical Trials Group sub-study A5334s
© 2019 The British Pharmacological Society..
AIMS: AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfected adults. The pharmacokinetics of OBV/PTV/r + DSV during raltegravir coadministration were also characterized.
METHODS: Adults living with HIV/HCV coinfection receiving steady-state raltegravir (400 mg twice daily) with 2 nucleos(t)ide analogues were enrolled. Pharmacokinetics of raltegravir were assessed prior to HCV therapy, and 4 weeks later following initiation of OBV/PTV/r (25/150/100 mg) once daily + DSV (250 mg) twice daily. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) were used to compare the following: raltegravir pharmacokinetics with HCV therapy (week 4) vs before HCV therapy (week 0); OBV/PTV/r and DSV pharmacokinetics vs historical healthy controls; raltegravir pharmacokinetics at week 0 vs historical control adults living with HIV.
RESULTS: Eight of 11 participants had decreased raltegravir exposures after initiation of HCV therapy. The GMRs (90% CI) for maximum concentration and area under the concentration-time curve of raltegravir with vs without HCV therapy were 0.68 (0.38-1.19) and 0.82 (0.58-1.17), respectively. Comparing OBV/PTV/r pharmacokinetics in healthy controls, A5334s study participants demonstrated generally lower maximum concentration and area under the concentration-time curve values by 41-82% and 4-73%, respectively. Raltegravir exposures tended to be higher in A5334s study participants compared to adults living with HIV.
CONCLUSIONS: The majority of participants' plasma raltegravir exposures were lower after initiation of HCV therapy in coinfected adults; however, confidence intervals were wide.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
---|---|
Enthalten in: |
British journal of clinical pharmacology - 86(2020), 1 vom: 22. Jan., Seite 132-142 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Venuto, Charles S [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 26.07.2021 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/bcp.14148 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM302608184 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM302608184 | ||
003 | DE-627 | ||
005 | 20240214232142.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/bcp.14148 |2 doi | |
028 | 5 | 2 | |a pubmed24n1292.xml |
035 | |a (DE-627)NLM302608184 | ||
035 | |a (NLM)31656054 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Venuto, Charles S |e verfasserin |4 aut | |
245 | 1 | 0 | |a Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus-1 and hepatitis C virus coinfection |b AIDS Clinical Trials Group sub-study A5334s |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.07.2021 | ||
500 | |a Date Revised 14.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2019 The British Pharmacological Society. | ||
520 | |a AIMS: AIDS Clinical Trials Group study A5334s evaluated the pharmacokinetics of raltegravir before and during combined administration of ombitasvir, paritaprevir/ritonavir, plus dasabuvir (OBV/PTV/r + DSV) and weight-based ribavirin in human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfected adults. The pharmacokinetics of OBV/PTV/r + DSV during raltegravir coadministration were also characterized | ||
520 | |a METHODS: Adults living with HIV/HCV coinfection receiving steady-state raltegravir (400 mg twice daily) with 2 nucleos(t)ide analogues were enrolled. Pharmacokinetics of raltegravir were assessed prior to HCV therapy, and 4 weeks later following initiation of OBV/PTV/r (25/150/100 mg) once daily + DSV (250 mg) twice daily. Geometric mean ratios (GMRs) and 90% confidence intervals (CIs) were used to compare the following: raltegravir pharmacokinetics with HCV therapy (week 4) vs before HCV therapy (week 0); OBV/PTV/r and DSV pharmacokinetics vs historical healthy controls; raltegravir pharmacokinetics at week 0 vs historical control adults living with HIV | ||
520 | |a RESULTS: Eight of 11 participants had decreased raltegravir exposures after initiation of HCV therapy. The GMRs (90% CI) for maximum concentration and area under the concentration-time curve of raltegravir with vs without HCV therapy were 0.68 (0.38-1.19) and 0.82 (0.58-1.17), respectively. Comparing OBV/PTV/r pharmacokinetics in healthy controls, A5334s study participants demonstrated generally lower maximum concentration and area under the concentration-time curve values by 41-82% and 4-73%, respectively. Raltegravir exposures tended to be higher in A5334s study participants compared to adults living with HIV | ||
520 | |a CONCLUSIONS: The majority of participants' plasma raltegravir exposures were lower after initiation of HCV therapy in coinfected adults; however, confidence intervals were wide | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a HIV/AIDS | |
650 | 4 | |a antiretrovirals | |
650 | 4 | |a drug interactions | |
650 | 4 | |a hepatitis | |
650 | 4 | |a pharmacokinetics | |
650 | 7 | |a Anilides |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Cyclopropanes |2 NLM | |
650 | 7 | |a Lactams, Macrocyclic |2 NLM | |
650 | 7 | |a Macrocyclic Compounds |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
650 | 7 | |a ombitasvir |2 NLM | |
650 | 7 | |a 2302768XJ8 |2 NLM | |
650 | 7 | |a Raltegravir Potassium |2 NLM | |
650 | 7 | |a 43Y000U234 |2 NLM | |
650 | 7 | |a Uracil |2 NLM | |
650 | 7 | |a 56HH86ZVCT |2 NLM | |
650 | 7 | |a Proline |2 NLM | |
650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
650 | 7 | |a 2-Naphthylamine |2 NLM | |
650 | 7 | |a CKR7XL41N4 |2 NLM | |
650 | 7 | |a dasabuvir |2 NLM | |
650 | 7 | |a DE54EQW8T1 |2 NLM | |
650 | 7 | |a Valine |2 NLM | |
650 | 7 | |a HG18B9YRS7 |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a paritaprevir |2 NLM | |
650 | 7 | |a OU2YM37K86 |2 NLM | |
700 | 1 | |a Cramer, Yoninah S |e verfasserin |4 aut | |
700 | 1 | |a Rosenkranz, Susan L |e verfasserin |4 aut | |
700 | 1 | |a Sulkowski, Mark |e verfasserin |4 aut | |
700 | 1 | |a Wyles, David L |e verfasserin |4 aut | |
700 | 1 | |a Cohen, Daniel E |e verfasserin |4 aut | |
700 | 1 | |a Schmidt, Jeffrey |e verfasserin |4 aut | |
700 | 1 | |a Alston-Smith, Beverly L |e verfasserin |4 aut | |
700 | 1 | |a Morse, Gene D |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 86(2020), 1 vom: 22. Jan., Seite 132-142 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
773 | 1 | 8 | |g volume:86 |g year:2020 |g number:1 |g day:22 |g month:01 |g pages:132-142 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.14148 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 86 |j 2020 |e 1 |b 22 |c 01 |h 132-142 |